Scholarlink

<p>Anaplastic pancreatic carcinoma (APC) is an extremely rare and aggressive histological subtype of pancreatic cancer with a poor prognosis. The therapeutic significance of <i>BRCA1/2</i> mutations, which are established targets in pancreatic ductal adenocarcinoma (PDAC), remains unclear in APC. We report the case of a man in his 70s diagnosed with metastatic pleomorphic APC. Germline testing revealed a pathogenic <i>BRCA2</i> variant. After achieving stable disease with 5 months of platinum-based chemotherapy (mFOLFIRINOX), he was transitioned to maintenance therapy with the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib. Olaparib maintained stable disease for 18 months. Although his clinical course was complicated by a concurrent sigmoid colon cancer, the patient remains alive at 47 months post-diagnosis. To the best of our knowledge, this case is the first to report long-term disease control with a PARP inhibitor in a patient with <i>BRCA2</i>-mutated APC of the pleomorphic (non-osteoclast-like giant cell) subtype. Our findings suggest the potential efficacy of a “platinum-based therapy followed by PARP maintenance” strategy in <i>BRCA</i>-mutated APC and highlight the importance of early germline <i>BRCA</i> testing.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Long-term survival in a patient with BRCA2-mutated pleomorphic anaplastic pancreatic carcinoma treated with Olaparib maintenance therapy

  • 期刊论文

  • 发表日期：

    2026年2月15日

查看全文
  • Jun Kubota,
  • Sakue Masuda,
  • Makomo Makazu,
  • Karen Kimura,
  • Shunsuke Imaeda,
  • Shinichi Teshima,
  • Keitaro Wada,
  • Kazuya Koizumi

摘要

Anaplastic pancreatic carcinoma (APC) is an extremely rare and aggressive histological subtype of pancreatic cancer with a poor prognosis. The therapeutic significance of BRCA1/2 mutations, which are established targets in pancreatic ductal adenocarcinoma (PDAC), remains unclear in APC. We report the case of a man in his 70s diagnosed with metastatic pleomorphic APC. Germline testing revealed a pathogenic BRCA2 variant. After achieving stable disease with 5 months of platinum-based chemotherapy (mFOLFIRINOX), he was transitioned to maintenance therapy with the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib. Olaparib maintained stable disease for 18 months. Although his clinical course was complicated by a concurrent sigmoid colon cancer, the patient remains alive at 47 months post-diagnosis. To the best of our knowledge, this case is the first to report long-term disease control with a PARP inhibitor in a patient with BRCA2-mutated APC of the pleomorphic (non-osteoclast-like giant cell) subtype. Our findings suggest the potential efficacy of a “platinum-based therapy followed by PARP maintenance” strategy in BRCA-mutated APC and highlight the importance of early germline BRCA testing.